New study challenges accepted approaches to research in senile dementia
- Details
- Category: Research
Impacting millions of families and devouring billions of dollars globally, Alzheimer's disease is the focus of exhaustive research to find a cure. Although intensely investigated over the last three decades using cutting-edge technologies, the "pathogenic cause" of Alzheimer's disease has not been found.
'Vampire' Bacteria Has Potential as Living Antibiotic
- Details
- Category: Research
A vampire-like bacteria that leeches onto specific other bacteria - including certain human pathogens - has the potential to serve as a living antibiotic for a range of infectious diseases, a new study indicates.
Bio-Images and Medimetrics Partner to Deliver the Next Generation of Smart Pill Technology
- Details
- Category: Development
Bio-Images Research and Medimetrics Personalized Drug Delivery have today announced a partnership to introduce the IntelliCap to the global pharmaceutical industry as a clinical research tool.
Innovative technology improves care and reduces costs
- Details
- Category: Development
The use of long-distance video and data hookups to link remote community hospitals with stroke neurologists in large centres provides the same level of care as having everyone in the same room, according to a new study presented today at the Canadian Stroke Congress.
Colorectal cancer drug may cause permanent nerve damage
- Details
- Category: Research
Oxaliplatin, a platinum-based anticancer drug that's made enormous headway in recent years against colorectal cancer, appears to cause nerve damage that may be permanent and worsens even months after treatment ends.
ecancerHub - A New Approach to Cancer Communication
- Details
- Category: Development
eurocancercoms has announced the launch of ecancerHub - a new, open-access, integrated approach to providing the whole cancer community - patients, doctors, researchers and policymakers - with high quality and trustworthy information.
Genetically modified 'serial killer' T cells obliterate tumors in leukemia patients
- Details
- Category: Research
In a cancer treatment breakthrough 20 years in the making, researchers from the University of Pennsylvania's Abramson Cancer Center and Perelman School of Medicine have shown sustained remissions of up to a year among a small group of advanced chronic lymphocytic leukemia (CLL) patients treated with genetically engineered versions of their own T cells.
More Pharma News ...
- Innovative Medicines Initiative (IMI) 4th Call 2011
- CONTRACT's Questionnaire to Analyse and Improve Informed Consent in Clinical Trials
- ASCO Launches Cancer.Net Mobile, a New App for iPhone, iPad, and iPod Touch
- IMI announces a new total of 23 unique projects to boost drug innovation
- Harvard Medical School Faculty Advances Drug Safety Research with IBM Business Analytics
- New potential drug targets discovered for preventing prostate cancer cell growth
- Which Pharma Product Websites are Driving Consumers to the Doctor to Request Prescriptions?